If you have an oncology condition you may be eligible to participate in a patient clinical trial for the condition.
The team here at Scientia Clinical Research would love to welcome you on a clinical trial, but first you will need a medical referral letter including all relevant treatment and diagnostic information. You may also speak to your oncology consultant, and they will be able to contact us if you are a suitable candidate for referral.
To facilitate prompt review of referral, please include the following:
- A clinical trial referral letter
- Medical and treatment history
- Most recent blood test and scan results
- Histopathology or biopsy reports
- Molecular pathology result, if available
- Contact details of referring doctor
If you have have any questions please email our team at : ContactUs@scientiaclinicalresearch.com.au
80948543LYM1001
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL
Location
Randwick, Sydney
Category
Advanced Solid Tumours
AMT-676-01
First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Location
Randwick, Sydney
Category
Advanced solid tumours, gastrointestinal tumours of are interest
AMX-818-001
A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of AMX-818 Alone and in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic HER2-Expressing Cancers
Location
Randwick, Sydney
Category
Locally Advanced or Metastatic HER2-Expressing Cancers
ATG-101-001
A First-in-Human Phase I Trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas. “PROBE Study”
Location
Randwick, Sydney
Category
Advanced Solid Tumours and Mature B-cell NHL
AXA-042-FIH-01
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumors.
Location
Randwick, Sydney
Category
Advanced Solid Tumours
BL0020-101
Location
Category
CIBI130A101
Location
Category
CIBI3004A101
A Phase Ⅰ/Ⅱ, Multicenter, Open-label Study of IBI3004 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors
Location
Randwick, Sydney
Category
Advanced solid tumours, gastrointestinal tumours of are interest
CIBI133A101
A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours
Location
Category
CL1-95035-001
A Phase 1, open-label, multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP
Location
Randwick, Sydney
Category
Participants with MTAP-deleted solid tumors
CP-MVC-101-01
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
Location
Randwick, Sydney
Category
Unresectable Locally Advanced or Metastatic Cancer, Non-small Cell Lung Cancer, Head and Neck Squamous cell carcinoma
CS5001-101
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas
Location
Randwick, Sydney
Category
Advanced Solid Tumours and Lymphomas
DB-1303-O-1001
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors
Location
Category
DB-1311-0-1001
A Phase 1/2a, multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumours.
Location
Category
DB-1419-O-1001
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors
Location
Randwick, Sydney
Category
Advanced/Metastatic Solid Tumors
DCSZ11-101
A Phase 1, Multicenter, Open-label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumour Activity of DCSZ11 as a Monotherapy in Patients with Advanced or metastatic Solid Tumours
Location
Category
EIK1003-001 (IMP1734-101)
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors
Location
Randwick, Sydney
Category
Adult participants and with solid tumors as monotherapy
ES009-1001
Location
Randwick, Sydney
Category
IMC-F106C-101
A Phase 1 / 2 First-in-human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01- Positive Participants with Advanced PRAME-Positive Cancers
Location
Category
Advanced Positive Cancers
JNJ-87801493
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
Location
Randwick, Sydney
Category
Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
JSKN033-101
Phase I/II Study to Assess the Safety, tolerability, Pharmacokinetics and efficacy of JSKN033 in Patients with Advanced or Metastatic Solid Malignant Tumors
Location
Category
HER2-expressing Advanced or Metastatic Solid Tumours
MDNA11-01
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors. “ABILITY Study”
Location
Randwick, Sydney
Category
Advanced Solid Tumours
MTX-TROP2-302
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmcodynamics and Preliminary Efficacy of MT-302 in Adults with Advanced or Metastatic Epithelial Tumors.
Location
Category
NST-628-001
A Phase 1, open label single-arm two-part study to investigate safety,
pharmacokinetics, and preliminary efficacy of pan-RAF/MEK glue NST-628
oral tablets in subjects with solid tumors harboring genetic alterations in the
MAPK pathway and with other solid tumors
Location
Randwick, Sydney
Category
Solid tumors harboring genetic alterations in the MAPK pathway and with other solid tumors
OXT328
We are conducting a study to test a potential treatment for nerve damage following chemotherapy.
If you have induced nerve damage as a result of chemotherapy and have completed chemotherapy between one to six months ago and are aged 18 years of age or older, you may be interested in participating in our study.
Location
Randwick, Sydney
SCTB14-X101
A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB14 in Patients With Advanced Malignant Solid Tumours
Location
Randwick, Sydney
Category
Adult Patients With Advanced Malignant Solid Tumours
SHR-A1904-I-104
AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS EXPRESSING CLAUDIN 18.2
Location
Randwick, Sydney
Category
Advanced Solid Tumours
SR-8541A-001
Location
Category
Advanced Metastatic Solid Tumours
SVN1521-101
A multi-center, open-label Phase 1 trial of SNV1521 administered orally as a single agent, to evaluate the safety, tolerability, preliminary anti-tumor activity and determine the maximum
tolerated dose (MTD) and RDE(s) of monotherapy SNV1521 in adult participants with advanced solid tumors
Location
Randwick, Sydney
Category
Adult participants and with solid tumors as monotherapy
We also conduct Healthy Volunteer Clinical trials which may be of interest for people with no medical conditions.
